RxDoctor Payments Data

Douglas Magenheim, MD

Internal Medicine · Cincinnati, OHNPI 1871574780

Payments from drug & device makers

$9,744in general payments, 2019–2025

Across 535 payments — averaging $18.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$2K
  • Pfizer$999
  • Amgen$787
  • AbbVie$666
  • Novartis$534
  • plus $4K from 42 others

What the payments were for

  • Food & beverage$9,64499%
  • Education$1011%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,744 in reported general payments places this provider in the 90th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$139,384
Medicare patients
275
Services billed
14,428

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban167$180,725
MounjaroTirzepatide94$127,070
OzempicSemaglutide82$86,822
FarxigaDapagliflozin Propanediol78$86,620
TivicayDolutegravir Sodium12$53,245
JardianceEmpagliflozin48$46,590
Trelegy ElliptaFluticasone/Umeclidin/Vilanter47$44,559
EntrestoSacubitril/Valsartan34$36,878
MyrbetriqMirabegron36$28,686
GemtesaVibegron37$27,954
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog17$27,164
PifeltroDoravirine12$20,763
Repatha SureclickEvolocumab28$19,864
ProliaDenosumab11$19,046
ArexvyRsvpref3 Antigen/As01e/Pf53$16,224

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Prempro$999$183,579179 claims
Lilly USA, LLCMounjaro$364$127,07094 claims
Novo NordiskOzempic$1,620$86,82282 claims
AstraZenecaFarxiga$1,619$86,62078 claims
GSKTrelegy Ellipta, Arexvy, Shingrix$205$63,857114 claims
Boehringer IngelheimJardiance$71$46,59048 claims
NovartisEntresto$534$36,87834 claims
MerckPifeltro, Lagevrio (Eua)$261$35,86333 claims
Astellas Pharma US IncMyrbetriq$108$28,68636 claims
Sumitomo Pharma America, Inc.Gemtesa$86$27,95437 claims
AbbVieRestasis, Linzess, Synthroid$666$22,28793 claims
AmgenProlia$787$19,04611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →